A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

被引：14

作者：

Paz-Ares, L. ^{[1
]}

del Muro, J. G. ^{[2
]}

Grande, E. ^{[3
]}

Diaz, S. ^{[4
]}

机构：

[1] Hosp 12 Octubre, Dept Oncol, E-28041 Madrid, Spain

[2] Catalan Inst Oncol, Dept Oncol, Barcelona, Spain

[3] Pfizer Spain, Med Unit, Dept Oncol, Madrid, Spain

[4] Pfizer Spain, Med Unit, Dept Hlth Outcomes Res, Madrid, Spain

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2010年 / 35卷 / 04期

关键词：

cost-effectiveness; metastatic renal cell carcinoma; second line; Spain; sunitinib; ECONOMIC-EVALUATION; KIDNEY CANCER; SURVIVAL; NEPHRECTOMY; THERAPY; MALATE;

D O I：

10.1111/j.1365-2710.2009.01135.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P>Aim: To investigate the cost-effectiveness of sunitinib (50 mg/day, schedule 4/2) vs. best supportive care (BSC) in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC), from the perspective of the Spanish National Health Service. Material and Methods: A Markov model compared the cost-effectiveness (taking into account drugs; medical visits; laboratory tests; X-rays; terminal care; adverse event management) of sunitinib and BSC across three disease states: no progression, survival with progression and death from mRCC or other causes. Results: The monthly incremental cost-effectiveness ratio (ICER) values for sunitinib treatment were euro6073/progression-free survival month, euro25 199/life years and euro34 196/quality-adjusted life years (QALY) gained. In 95% of cases, the ICER/QALY values were below the accepted euro45 000/QALY threshold. Efficacy and cost of sunitinib had the greatest impact on cost-effectiveness. Conclusion: Sunitinib has a good cost-effectiveness profile in mRCC. The cost per life year and QALY gained is affordable according to current effectiveness thresholds in developed countries.

引用

页码：429 / 438

页数：10

共 50 条

[21] A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma [J].

Reinhorn, Daniel ;

Sarfaty, Michal ;

Leshno, Moshe ;

Moore, Assaf ;

Neiman, Victoria ;

Rosenbaum, Eli ;

Goldstein, Daniel A. .

ONCOLOGIST, 2019, 24 (03) :366-371

[22] Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments [J].

De Groot, S. ;

Blommestein, H. M. ;

Redekop, W. K. ;

Sleijfer, S. ;

Kiemeney, L. A. L. M. ;

Oosterwijk, E. ;

Uyl-de Groot, C. A. .

PLOS ONE, 2017, 12 (05)

[23] A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan [J].

Tomura, Kazuki ;

Naito, Yuki ;

Sunaga, Tomiko ;

Kurihara, Tatsuya ;

Usuda, Masahiro ;

Nagatani, Akiko ;

Ogawa, Yumiko ;

Akiyama, Nao ;

Sasaki, Haruaki ;

Murata, Tatsunori ;

Sakamaki, Hiroyuki ;

Kogo, Mari ;

Sasaki, Tadanori .

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (11) :1397-1407

[24] Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System [J].

Bai, Yongrui ;

Xu, Yuejuan ;

Wu, Bin .

GASTROENTEROLOGY RESEARCH AND PRACTICE, 2017, 2017

[25] Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective [J].

Driessen, M. T. ;

Whalen, J. ;

Buguth, B. Seewoodharry ;

Vallejo-Aparicio, L. A. ;

Naya, I. P. ;

Asukai, Y. ;

Alcazar-Navarrete, B. ;

Miravitlles, M. ;

Garcia-Rio, F. ;

Risebrough, N. A. .

RESPIRATORY RESEARCH, 2018, 19

[26] Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective [J].

M. T. Driessen ;

J. Whalen ;

B. Seewoodharry Buguth ;

L. A. Vallejo-Aparicio ;

I. P. Naya ;

Y. Asukai ;

B. Alcázar-Navarrete ;

M. Miravitlles ;

F. García-Río ;

N. A. Risebrough .

Respiratory Research, 19

[27] A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma [J].

Chan, Alan ;

Dang, Carolyn ;

Wisniewski, Jessica ;

Weng, Xiuhua ;

Hynson, Edward ;

Zhong, Lixian ;

Wilson, Leslie .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (02) :66-73

[28] Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource-Limited Setting [J].

Wu, Bin ;

Dong, Baijun ;

Xu, Yuejuan ;

Zhang, Qiang ;

Shen, Jinfang ;

Chen, Huafeng ;

Xue, Wei .

PLOS ONE, 2012, 7 (03)

[29] Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies [J].

Castellano, Daniel ;

Pablo Maroto, Jose ;

Espinosa, Enrique ;

Grande, Enrique ;

Victoria Bolos, M. ;

Llinares, Julia ;

Esteban, Emilio ;

Gonzalez del Alba, Aranzazu ;

Angel Climent, Miguel ;

Angel Arranz, Jose ;

Jose Mendez, Ma ;

Fernandez Parra, Eva ;

Anton-Aparicio, Luis ;

Bayona, Cristina ;

Gallegos, Isabel ;

Gallardo, Enrique ;

Samaniego, Luz ;

Garcia Donas, Jesus .

EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) :573-579

[30] Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System [J].

Matter-Walstra, Klazien ;

Joerger, Markus ;

Kuehnel, Ursula ;

Szucs, Thomas ;

Pestalozzi, Bernhard ;

Schwenkglenks, Matthias .

VALUE IN HEALTH, 2012, 15 (01) :65-71

← 1 2 3 4 5 →